Form 4: Director An van Es-Johansson Acquires PLUS Therapeutics Stock

An van Es-Johansson, a Director at PLUS THERAPEUTICS, INC., has acquired restricted stock units and stock options.

Summary

• Director An van Es-Johansson acquired 3,686 Restricted Stock Units (RSUs) and 3,686 stock options on May 14, 2026.
• The RSUs vest ratably over four quarters, with the first 1/4 vesting on July 1, 2026, and subsequent vesting occurring quarterly.
• The stock options vest monthly over 12 months from the grant date, with full vesting possible on the Issuer's 2027 Annual Stockholder Meeting, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity award to a director, indicating continued engagement and alignment with company performance.

Positives

• Director's acquisition of equity indicates confidence in the company's future prospects.
• The vesting schedule for RSUs and stock options aligns with continued service and company milestones.

Risks

• Vesting of RSUs and stock options is contingent on continued service, implying potential forfeiture if service is terminated.
• The value of the acquired securities is subject to market fluctuations and the company's performance.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a forward-looking incentive structure tied to continued employment and company performance.

Industry Context

StockSavvy.ai notes that the acquisition of equity by a director is a common practice in the biotechnology and pharmaceutical sectors, often used to align executive interests with shareholder value and incentivize long-term commitment.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, signaling commitment, but the direct financial impact is minimal as it's an award rather than an open market purchase.
• Employees: The vesting structure for options and RSUs can serve as an incentive for other employees if similar programs are in place.
• Management: Reinforces the alignment of director compensation with company performance and long-term value creation.

Next Steps

• Continued service by An van Es-Johansson to meet vesting requirements for RSUs and stock options.
• Quarterly vesting of RSUs commencing July 1, 2026.
• Monthly vesting of stock options over 12 months.

Key Dates

Keywords

PLUS THERAPEUTICS, PSTV, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, SEC Filing, Equity Award